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Background: Several tools have been proposed for serodiagnosis of cystic echinococcosis (CE), but none seems promising for 
cyst viability assessment. Antigens with stage-specific diagnostic value have been described, but few studies with well-characterized 
antigens and human serum samples have been performed. Antigen B (AgB) proteoforms hold promise as markers of viability, due to 
their differential stage-related expression and immunoreactivity.
Methods: Four AgB subunits (AgB1, AgB2, AgB3, AgB4) were synthesized and structurally characterized. Based on the prelim-
inary evaluation of the subunits by western immunoblotting and enzyme-linked immunosorbent assay (ELISA), AgB1 and AgB2 
were further tested in two ELISA setups and extensively validated on 422 human serum samples.
Results: All subunits showed a high degree of spontaneous oligomerization. Interacting residues within oligomers were iden-
tified, showing that both the N-terminal and C-terminal of each subunit are involved in homo-oligomer contact interfaces. No 
hetero-oligomer was identified. AgB1 and AgB2 ELISAs revealed different sensitivities relative to cyst stage. Of note, besides high 
specificity (97.2%), AgB1 revealed a higher sensitivity for active-transitional cysts (100% for CE1, 77.8% for CE2, 81.5% for CE3a, 
and 86.3% for CE3b) than for inactive cysts (41.7% for CE4 and 11.1% for CE5) and postsurgical patients (44%). Interestingly, 19 of 
20 patients with spontaneously inactive cysts and 6 of 9 treated with albendazole >5 years earlier were negative on the AgB1 assay.
Conclusions: The structural characterization of subunits provides insights into the synthetic antigen conformation. The stage-re-
lated sensitivity of synthetic AgB1 holds promise as part of a multiantigen setting and deserves further longitudinal evaluation as 
marker of cyst viability.
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Cystic echinococcosis (CE) is a neglected zoonotic disease 
caused by the larval stage of the parasite Echinococcus granulo-
sus sensu lato and represents a worldwide public health and eco-
nomic issue. The life cycle typically includes sheep, goats, swine, 
and cattle among others as intermediate hosts, and canids as 
definitive hosts, and the parasite is particularly widespread in 
livestock breeding areas [1]. Humans may act as accidental 
intermediate hosts by ingestion of parasite eggs in contami-
nated material. After infection, fluid-filled cysts develop that 
can localize in different organs, mostly liver and lungs, and may 
remain asymptomatic for years.
Although imaging, especially ultrasonography (US) for 
abdominal localization, is the most reliable tool for diagnosis of 
CE, serology is a useful complementary tool. However, the per-
formances of current serological tests are unsatisfactory [2, 3].
The World Health Organization Informal Working Group on 
Echinococcosis international classification of US images classifies 
CE cysts in 6 stages [4, 5], which largely reflect the biological via-
bility of cysts: CE1, CE2, CE3b (CE1–2, active cysts, CE3b, transi-
tional cyst; all biologically viable), CE3a (transitional cyst; variable 
viability), and CE4 and CE5 (inactive cysts; biologically nonviable) 
[6]. However, the biological nonviability of inactive cysts cannot 
be predicted based on US appearance. In particular, CE4 cysts 
(inactive cysts with solid appearance at US) are in the vast major-
ity of cases nonviable when this stage is reached spontaneously 
[7–9], and a variable proportion of cases reactivate if CE4 has been 
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reached after medical treatment of an active stage, indicating bio-
logical viability [10, 11]. Hence the need for years-long follow-up 
with US to detect cyst reactivation after treatment, as currently 
available serological tests are not useful for this purpose [12].
Many investigations evaluated the diagnostic performances of 
synthetic, native, or recombinant purified antigens of E. granu-
losus. Antigen 5 (Ag5) and antigen B (AgB) are by far the most 
exploited, owing to their abundance and immunogenic properties 
[13, 14]. AgB is an oligomeric thermostable lipoprotein encoded 
by 5 genes (AgB1–AgB5), composed of multimers of 8-kDa subu-
nits [15], mainly secreted by the germinal layer [16], and carrying 
a large amount of lipids of host origin, which account for almost 
50% of its mass. Several studies have investigated the reactivity of 
AgB1 and AgB2, the most abundant subunits in the native com-
plex [17]. AgB has also been structurally investigated [18–22], re-
vealing an α-helix–rich configuration, with a high propensity to 
oligomerize in both the native and recombinant forms.
Given their abundance and immunogenicity, both Ag5 and AgB 
have been often proposed as targets in serological assays. However, 
mixed results have been obtained for these antigens in terms of 
sensitivity and specificity [13, 14], probably owing to the use of dif-
ferent experimental conditions, different panels of serum samples, 
limited number of samples, poor interlaboratory reproducibility 
of antigen preparation, and lack of information about the antigen 
structure, that can heavily affect its immunoreactivity [2, 23, 24].
To this aim, we have previously highlighted the critical role of a 
high-quality purification of native Ag5 for developing highly spe-
cific serological assays [25, 26]. Different protein targets, includ-
ing Ag5 and high-quality products of the AgB gene variants, 
might be combined in a multiantigen test for enabling a more 
reliable serological diagnosis and providing useful indications on 
cyst viability. However, a rapid, high-quality, and high-yielding 
purification of native AgB variants represents an unmet chal-
lenge, and synthetic products would serve as an excellent alterna-
tive. However, the structural features of a given synthetic peptide 
deserve to be investigated to deepen the knowledge on the possi-
ble relationship between the in vitro obtained structures and their 
immunoreactivity in novel serological assays.
In this study, therefore, we characterized the structural features 
and evaluated the immunoreactivity of four synthetic proteins, 
corresponding to the subunits AgB1–AgB4, the main constitu-
ents of the native AgB complex [18]. We provide evidence of their 
propensity for oligomerization and report detailed information 
on interacting residues, as well as the first putative description of 
AgB homo-oligomers arrangement. Building on these well-char-
acterized synthetic antigens, we also extended the evaluation of 
the different immunoreactivities exhibited by AgB proteoforms 
carried out by Ahn and coworkers [17], to cyst stages. To this end, 
serum samples from a cohort of patients and healthy controls were 
tested against synthetic AgB1 and AgB2 in two enzyme-linked 
immunosorbent assay (ELISA) setups. The same serum samples 
were also assayed with the Ag5 setup [26]. We observed different 
sensitivities depending on the AgB subunit and cyst stage, and a 
good association between AgB1 negative ELISA results and the 
presence of untreated (ie, spontaneously inactivated) inactive 
cysts. The comparison of AgB and Ag5 ELISA results opens inter-
esting perspectives on the applicability of a multiantigen test for 
the assessment of cyst viability and follow-up of patients.
METHODS
A detailed description of methods is provided in Supplementary 
File S1.
Synthesis and Purification of AgB Subunits
AgB1, AgB2, AgB3, and AgB4 sequences (7.6, 8.2, 7.7, and 
8.2 kDa, respectively) were selected from the UniProtKB data-
base. Proteins were synthesized, purified, and verified using 
mass spectrometry (MS) [27, 28].
Size-Exclusion Chromatography
Size-exclusion chromatography (SEC) was performed in 50 
mM sodium phosphate, 150 mM NaCl, pH 7.4, on a AKTA 
Explorer 10 system. Elution profiles were recorded, based on 
the UV absorption at 220 and 280 nm.
Chemical Cross-Linking Experiments
Each AgB subunit or its equimolar mixture was treated with a 
100-fold molar excess of 1-ethyl-3-(3-dimethylaminopropyl)car-
bodiimide (EDC) cross-linking reagent; reactions were stopped, 
and samples were separated by sodium dodecyl sulfate–poly-
acrylamide gel electrophoresis (SDS-PAGE) [29]. Selected pro-
tein bands were in situ digested [30], and analyzed using liquid 
chromatography–tandem MS performed with a Q Exactive mass 
spectrometer [31] interfaced with an UltiMate 3000 RSLCnano 
liquid chromatography system. Cross-linked peptides were iden-
tified using StavroX software (version 3.3.0.1) [32].
Western Immunoblotting
Western immunoblotting was performed as described else-
where [25]. Membranes were incubated with 1:200 Working 
Standard Anti-Echinococcus Serum, Human (WSH serum).
Serum Samples
A total of 422 blood serum samples were collected, including 
148 from patients with CE cysts, 25 from patients who had pre-
viously been treated surgically for CE and in follow-up at the 
time of serum collection (after surgery), and 249 from healthy 
subjects. Table 1 summarizes the number of patients available 
for each group and the corresponding cyst location.
ELISA
ELISA was performed as described elsewhere [26]. Serum samples 
were added at 1:200 dilutions to microplates coated with 100 µL per 
well of antigen solutions in phosphate-buffered saline. To compare 
results obtained from different plates, we calculated a sample ratio .
Statistical Analysis
Data analysis was performed with MedCalc statistical software, 
version 15.2.2. Receiver operating characteristic (ROC) curves, 
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McNemar test, and Kruskal-Wallis test were applied to data 
sets, as reported elsewhere [26, 33–36].
RESULTS
Structural Characterization of AgB Subunits
The oligomeric state of AgB1–AgB4 synthetic subunits was 
investigated by SEC and cross-linking experiments. SEC was 
performed on the four subunits to study their quaternary 
structure in phosphate buffer (Figure 1). AgB1 chromatography 
demonstrated a single main peak with an elution volume corre-
sponding to a molecular weight of about 66 kDa, in agreement 
with an octamer/nonamer (8.8 units) and a very small peak at 
the dimer’s elution volume (17 kDa). For AgB2 and AgB3, a 
single peak was observed (about 56 and 51 kDa, respectively), 
both corresponding to esameric/eptameric structures (6.8 and 
6.6 units, respectively). AgB4 exhibited only a very small peak, 
Table 1. Patient Grouping According to Clinical Characteristics and Location of the Cysts With the Stage Likely Most Influencing Their Serological Status
Group
Patients, No. Patients, No. (%)
Total No Albendazole Treatment Albendazole <5 y Earliera Albendazole >5 y Earlierb Hepatic Cysts Extrahepatic Cysts
CE1 7 2 5 0 7 (100.0) 0
CE2 9 2 7 0 9 (100) 0
CE3a 27 7 20 0 26 (96.3) 1 (3.7)
CE3b 51 14 37 0 44 (86.3) 7 (13.7)
CE4 36 8 23 5 34 (94.4) 2 (5.6)
CE5 18 12 2 4 16 (88.9) 2 (11.1)
Postsurgical 25 0 25 0 21 (84.0) 4 (16.0)
Total 173 45 119 9 157 (90.8) 16 (9.2)
aAlbendazole intake ended <5 years before collection of serum samples for this study.
bAlbendazole intake ended >5 years before collection of serum samples for this study.
Figure 1. Size-exclusion chromatography of the synthetic antigen B (AgB) subunits. The chromatogram overlay of AgB1, AgB2, AgB3, and AgB4 shows their similar propen-
sity to oligomerize. (AgBm)n indicates the n units forming the AgBm oligomer. Size calibration marks, obtained from runs of standard proteins aprotinin (6.5 kDa), ribonuclease 
A (13.7 kDa), carbonic anhydrase (29 kDa), ovalbumin (44 kDa), conalbumin (75 kDa) and blue dextran 2000 (as void volume V0) are indicated by arrowheads in the chromatogram.
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probably owing to solubilization issues or a high propensity to 
aggregate, at an apparent molecular weight of about 51 kDa 
(esamer).
Cross-linking experiments with EDC were performed to cova-
lently stabilize the quaternary structure reached by each subunit or 
an equimolar mixture of the four proteins, to allow self-assembling 
in heteromeric complexes. Products were separated by SDS-
PAGE in reducing and nonreducing conditions (Figure 2A 
and 2B for single subunits and Supplementary Figure S1A–S1B 
for the mixture, respectively). AgB1 oligomers clearly showed 
the formation of covalent bonds among subunits on the add-
ition of EDC, leading to the appearance of bands putatively 
Figure 3. Interacting residues from mass spectrometric analysis of protein bands after incubation of single subunits with 1-ethyl-3-(3-dimethylamino propyl)-carbodiim-
ide. Abbreviation: AgB, antigen B.
Figure 2. Sodium dodecyl sulfate–polyacrylamide gel electrophoresis of synthetic antigen B (AgB) subunits and their cross-linking products under reducing (A) and nonre-
ducing conditions (B). Lanes 1, 3, 5 and 7 correspond to the individual subunits without the addition of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) reagent. Lanes 
2, 4, 6, and 8 correspond to the individual subunits after incubation with EDC reagent. Abbreviation: M, molecular weight markers.
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corresponding to dimers, trimers, and tetramers (Figure 2A and 
2B, lane 2). Although for AgB2, AgB3, AgB4, and the mixture 
the effect of cross-linking was less evident, the gel bands puta-
tively containing their dimers, trimers, tetramers, and, for the 
mixture, high-molecular-weight species, were also excised and 
analyzed by MS; the monomeric bands were analyzed as a con-
trol, to deplete signals deriving from internal cross-links.
After careful attribution of all the interacting residues also 
found in the monomeric bands, StavroX software analysis, and 
manual check of the spectra, a series of cross-linked peptides was 
detected. Results are summarized in Figure 3, Supplementary 
Figure S2 and Supplementary File S2; the tandem MS spec-
trum of a cross-linked peptide is shown, as an example, in 
Supplementary Figure S3.
All the evaluated combinations provided information about 
cross-linked residues, revealing interactions involving both N- 
and C-terminal regions. The distribution of interacting residues 
was quite similar among the different subunits, both when they 
underwent cross-linking by themselves and in the mixture. No 
hetero-oligomer was identified, suggesting that, at least in our 
experimental conditions, subunits rearrange, also in an equi-
molar mixture, as homo-oligomers.
Immunoreactivity of AgB Subunits and Oligomers
The immunoreactivity of AgB1, AgB2, AgB3, and AgB4 subu-
nits, their combinations, and the corresponding cross-linked 
products were evaluated by western immunoblotting with WSH 
serum. Results are shown in Figure 4. Antigens were tested either 
Figure 4. Western immublotting of synthetic antigen B (AgB) subunits (A) and their cross-linking products after incubation with a 10-fold (B) or a 100-fold (C) excess of 
1-ethyl-3-(3-dimethylamino propyl)-carbodiimide under reducing conditions, as individual components, or as a mixture of the four subunits.
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as single AgB subunits or as an equimolar mixture. AgB1 showed 
the highest reactivity, followed by AgB4, AgB2, and AgB3, and 
the same trend was observed when the subunits were mixed. 
Noncovalent dimers (Figure 4A) were visible in the absence of 
EDC, highlighting the stability of their quaternary structure also 
in denaturing conditions. A 10-fold excess of cross-linker influ-
enced AgB1, for which a trimer was slightly evident (Figure 4B). 
A 100-fold excess of EDC, though not showing AgB2, AgB3, and 
AgB4 reactive oligomers, resulted in the appearance of the AgB1 
tetramer and pentamer, producing the classic ladderlike pattern 
of native AgB (Figure 4C and Supplementary Figure S4).
To assess the immunoreactivity of single AgB subunits and of 
different equimolar assortments also in non denaturing condi-
tions, 25 ng/well, 33 ng/well, 50 ng/well, and 100 ng/well of each 
protein solution were tested by ELISA, with the WSH serum.
The absorbance values revealed different immunoreactivities of 
the four subunits, according to the following trend: AgB1 > AgB2 
> AgB4 > AgB3 (Figure 5). No increase was observed when AgB1 
was mixed to any other subunit, compared with the same amount 
(100 ng) of AgB1 individually coated, whereas the other combina-
tions provided higher or lower absorbance values, depending on 
the antigens combined.
Validation of AgB1 and AgB2 ELISA Setups With a Large Collection of Ser 
Samples
AgB1 and AgB2, at 25 ng per well, were selected for individual val-
idation experiments on a large panel of human serum samples. To 
characterize and validate their immunoreactivity, 422 serum sam-
ples from individuals harboring CE cysts in different stages were 
analyzed by ELISA. The optimal cutoff values were calculated 
based on ROC curves (Figure 6 and Table 2). The areas under the 
Figure 6. Receiver operating characteristic (ROC) curve overlay of the antigen B1 
(AgB1) and antigen B2 (AgB2) enzyme-linked immunosorbent assay setups. Curves 
are generated by plotting sensitivity versus 100 − specificity.
Figure 5. Enzyme-linked immunosorbent assay absorbance values using the synthetic subunits as antigens. Different amounts of each synthetic subunit (25, 33, 50 and 
100 ng) and their equimolar combination (100 ng of total mixture) were evaluated against the Working Standard Anti-Echinococcus Human Serum. Dashed line indicates 
absorbance value obtained in the same conditions, on an uncoated well. Bars indicate standard deviations from the mean.
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ROC curve were 0.959 and 0.923 for AgB1 and AgB2, respectively. 
At the best sample ratio cutoff value (0.103 and 0.058 for AgB1 
and AgB2, respectively), AgB1 and AgB2 ELISAs showed very 
similar sensitivity toward patients with cysts in active-transitional 
stages (85.1 vs 84.0%; P = >.99) and postsurgical patients (44.0% 
vs 56.0%; P = .25) whereas differences were observed in patients 
with CE4 and CE5 cysts and healthy controls. 
The positive rates in patients with CE4 and CE5 cysts were 41.7% 
and 11.1%, respectively, for AgB1 ELISA, and 69.4% and 38.9% 
for AgB2 ELISA. The specificity of AgB1 was higher than that of 
AgB2 (97.2% vs 83.9%), as tested on serum samples from healthy 
controls. Results are summarized in Table 3. Both ELISAs discrim-
inated between patients and healthy controls (Figure 7A and 7B). 
Statistically significant differences were also found between patients 
with active-transitional versus inactive CE cysts (Figure 7C and 7D). 
Results obtained with serum samples according to cyst stages are 
shown in Figure 7E and 7F. AgB2 ELISA behaved differently from 
AgB1, because only patients with CE5 cysts and healthy donors 
showed significant differences from other subgroups.
Finally, AgB1 ELISA results were compared with those 
for Ag5 [26], using the same 422 serum samples (Table 4). 
Specificity was higher for AgB1 than for Ag5, although this 
difference was not statistically significant. Furthermore, AgB1 
was significantly less sensitive than Ag5 in detecting patients 
with cysts at any stage, but especially with inactive cysts. It is 
noteworthy that when patients with inactive cysts were fur-
ther grouped into patients with spontaneously inactivated (un-
treated) cysts, or treated with albendazole either <5 or >5 years 
previously (and thus inactivated as the result of treatment), 10 
of 20 untreated patients with inactive cysts, 23 of 25 treated with 
albendazole <5 years earlier, and 8 of 9 treated >5 years earlier, 
respectively, were positive to Ag5 (Figure 8A), compared with 
only 1 of 20, 13 of 25 and 3 of 9, respectively, to AgB1 (Figure 
8B). Moreover, when the same grouping was evaluated for 
patients with active-transitional cysts, Ag5 results were positive 
in 22 of 25 untreated patients and 68 of 69 who ended alben-
dazole intake <5 years before the collection of serum, whereas 
AgB1 results were positive in 21 of 25 and 58 of 69, respectively.
DISCUSSION
The search for a marker of cyst viability, to complement US stag-
ing, is one of the challenges in the field of clinical CE. The results 
of serodiagnostic tests are still unreliable from a clinical point of 
view. Several studies have been performed on small or medium/
large panels of human serum samples, mostly involving a limited 
number of immunodominant proteins [13, 14]. The most exten-
sively investigated and promising antigens are Ag5 and AgB, 
owing to their strong immunoreactivity and relatively high abun-
dance in hydatid fluid. Both have been tested as native, recom-
binant, and synthetic antigens [13, 14], with conflicting results. 
A number of features make AgB a good candidate biomarker of 
CE development and progression, including its primary secretion 
by the germinal layer cells [16], its putative involvement in the 
parasite lipid metabolism and as potential ligand for monocyte 
and macrophage receptors [22, 37], the variation of its relative 
abundance, specific oligomer assortments, and/or exposition to 
the immune system at different CE stages [17]. 
From a structural point of view, some information on this 
antigen was provided by other authors, both on recombi-
nant subunits and on the native AgB complex [18, 19, 38]. 
Understanding the protein conformation can help explain its 
immunoreactivity and provide information about the host-par-
asite interplay. Nevertheless, we are not aware of previous stud-
ies combining structural and immunological studies of this CE 
antigen. In the current study, we performed a detailed structural 
and immunodiagnostic investigation of the synthetic proteins 
constituting the four main subunits of the native AgB complex. 
Table 2. Statistical Parameters of AgB1 and AgB2 ELISA at the Best Cutoff Values
Antigen  Sensitivity, % Specificity, % AUC (SE) [95% CI] Youden Index
Likelihood Ratio
Positive Negative
AgB1 85.11 97.19 0.959 (0.012) [.932–.977] 0.8230 30.27 0.15
AgB2 84.04 83.94 0.923 (0.015) [.889–.949] 0.6798 5.23 0.19
Abbreviations: AgB1, antigen B1; AgB2, antigen B2; AUC, area under the (receiver operating characteristic) curve; CI, confidence interval; ELISA, enzyme-linked immunosorbent assay; SE, 
standard error. 
Table 3. ELISA Results by Group
Group Patients, No.
Positive by AgB1, 
No. (%)
Positive by AgB2, 
No. (%) P Value
Active-transitional
 Total 94 80 (85.1) 79 (84.0) >.99
 CE1 7 7 (100.0) 5 (71.4) .50
 CE2 9 7 (77.8) 8 (88.9) >.99
 CE3a 27 22 (81.5) 25 (92.6) .38
 CE3b 51 44 (86.3) 41 (80.4) .58
Inactive
 Total 54 17 (31.5) 32 (59.3) <.001a
 CE4 36 15 (41.7) 25 (69.4) .01a
 CE5 18 2 (11.1) 7 (38.9) .06
Postsurgical 25 11 (44.0) 14 (56.0) .25
Healthy controls 249 7 (2.8) 40 (16.1) <.001a
Abbreviations: AgB1, antigen B1; AgB2, antigen B2; ELISA, enzyme-linked immunosorbent 
assay.
aStatistically significant difference (McNemar test).
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According to the conformational studies, the ability of all the 
synthetic proteins to form oligomeric structures was shown 
for the first time. Our results suggest that the four subunits 
rearrange into highly organized structures, up to nonamers, 
and that interactions involve both the N- and the C-terminal 
regions, as the subunits would be organized in parallel and/or 
antiparallel bundles, maybe generating channels where lipids 
can be accommodated. 
As already suggested [18], we hypothesize that in vivo each sub-
unit may act as a nucleation center whose propagation leads to 
high-order oligomers, also building on the presence of other com-
pounds or external stimuli. Among the subunits, the most cross-
linked was AgB3, confirming the previous observation about a 
more compact structure that could also be responsible for a lower 
immunoreactivity [18]. Furthermore, the proposed mechanism 
Figure 7. Box-and-whiskers plots of enzyme-linked immunosorbent assay results for antigen B1 (AgB1) (left panels) and antigen B2 (AgB2) (right panels) setups. Boxes indi-
cate values falling within the 25th and 75th percentiles (interquartile range [IQR]). Central lines represent median values; whiskers, values falling within the ±1.5 IQR; single 
dots, values falling outside the whiskers; dashed lines, the best cutoff values. *Significantly different groups after Kruskal-Wallis test, or after Conover test, with Bonferroni 
correction, for multiple comparisons. According to this adjustment, to achieve statistical significance three P values have been considered: P < .05 for A and B, P < .02 for 
C and D, and P < .002 for panels E and F. Abbreviations: AT, active-transitional; H, healthy donors; I, inactive; P, patients; PS, postsurgical. 
Table 4. Ag5 ELISA Serological Results and Comparison With AgB1 ELISA
Group Patients, No. Positive by Ag5, No. (%) P Value
Active-transitional
 Total 94 90 (95.7) .03a
 CE1 7 7 (100.0) NA
 CE2 9 9 (100) .50
 CE3a 27 26 (96.3) .22
 CE3b 51 48 (94.1) .34
Inactive
 Total 54 41 (75.9) <.001a
 CE4 36 31 (86.1) <.001a
 CE5 18 10 (55.6) .008a
Postsurgical 25 19 (76.0) .008a
Healthy controls 249 13 (5.2) .21
Abbreviations: Ag5, antigen 5; AgB1, antigen B1; ELISA, enzyme-linked immunosorbent 
assay; NA, not applicable.
aStatistically significant difference (McNemar test). 
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might explain the lack of conformational data obtained by both 
structural approaches on AgB4, whose low solubility may be due 
to its high propensity to oligomerize up to aggregation.
Although showing a similarity with AgB3 in the distribution 
of contact residues, AgB1 and AgB2 results indicated a higher 
flexibility, which may be responsible for their higher immunore-
activity. Further studies are warrant to confirm these hypotheses 
and elucidate their relevance, if any, in host-parasite interplay. 
Moreover, our experimental conditions were not able to stabilize 
any hetero-oligomer, but other experiments, exploring differ-
ent setups and different approaches, would be required. Finally, 
AgB homo-oligomers partially survive SDS-PAGE (Figures 2 
and 4), although to a lesser extent than native AgB. Our results 
agree with the previous observation that self-assembly does not 
depend on the presence of lipids, but in their absence oligomers 
may be smaller than in the native complex [38].
Having demonstrated the ability of synthetic subunits to 
mimic the native antigen, we tested their immunoreactivity. 
Serological assays based on synthetic subunits showed a clear 
immunoreactivity with serum samples from patients with CE, 
using both Western immunoblotting and ELISA, with differ-
ences between assays mostly involving AgB4. The AgB4 behav-
ior might again be explained by the different assay conditions 
and the low solubility of AgB4 in phosphate buffer.
Both AgB1 and AgB2, the most reactive antigens, demon-
strated a good sensitivity to active-transitional stages. On the 
contrary, AgB1 especially was poorly sensitive in patients with 
inactive cysts and after surgery. When we further investigated 
this noteworthy result, we found that AgB1 was very poorly 
sensitive in patients with spontaneously inactive cysts (who 
had never received albendazole therapy) and those with inac-
tive cysts resulting from the treatment of active cysts (who had 
finished their last course of albendazole >5 years earlier and for 
which cysts is plausible to suppose biological nonviability). 
This finding suggests that AgB1 could be of use to discrim-
inate between inactive cysts that are no longer biologically via-
ble and those still biologically viable and therefore requiring a 
longer/closer follow-up with US to detect reactivation. However, 
these results need confirmation with a longitudinal study eval-
uating responses to AgB along the evolution of CE4 cysts over 
time. Our data also strongly support the use of both Ag5 and 
AgB1 in a multiantigen configuration, to provide both high sen-
sitivity for diagnosis of CE, and information on cyst viability, 
to guide the follow-up approach. Antigen combinations should 
be further explored to identify the optimal setup conditions for 
developing a highly performing diagnostic test.
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